One study identifies SLC2A1 may be a crucial glucose transporter in LUAD patients as SLC2A1 mRNA and protein levels are elevated in LUAD patients, and its overexpression is a potential indicator for lower differentiated tumor grade and poor prognosis (Younes et al., 1997a; Minami et al., 2002; Maki et al., 2013; Chai et al., 2017; Weng et al., 2018a; Guo et al., 2020). This evidence concerns the gene SLC2A1 and neoplasm.